[1] HENLEY SJ,WARD EM,SCOTT S,et al.Annual report to the nation on the status of cancer,part I:National cancer statistics［J］.Cancer,2020,126(10):2225-2249.
[2] SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA:a cancer journal for clinicians,2021,71(1):7-33.
[3] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:a cancer journal for clinicians,2021,71(3):209-249.
[4] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(1):19-28.
ZHENG RS,SUN KX,ZHANG SW,et al.Report of cancer epidemiology in China,2015［J］.Chinese Journal of Oncology,2019,41(1):19-28.
[5] CANCER GENOME ATLAS RESEARCH NETWORK,KANDOTH C,SCHULTZ N,et al.Integrated genomic characterization of endometrial carcinoma ［J］.Nature,2013,497(7447):67-73.
[6] TALHOUK A,MCCONECHY MK,LEUNG S,et al.A clinically applicable molecular-based classification for endometrial cancers［J］.British Journal of Cancer,2015,113(2):299-310.
[7] SMITH P,BAKOS O,HEIMER G,et al.Transvaginal ultrasound for identifying endometrial abnormality［J］.Acta Obstetricia Et Gynecologica Scandinavica,1991,70(7-8):591-594.
[8] SAMS SB,CURRENS HS,RAAB SS.Liquid-based papanicolaou tests in endometrial carcinoma diagnosis.Performance,error root cause analysis,and quality improvement［J］.American Journal of Clinical Pathology,2012,137(2):248-254.
[9] JIANG X,LI W,YANG J,et al.Identification of somatic mutations in papanicolaou smear DNA and plasma circulating cell-free DNA for detection of endometrial and epithelial ovarian cancers:a pilot study［J］.Frontiers in Oncology,2020,10:582546.
[10] WANG Y,LI L,DOUVILLE C,et al.Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers［J］.Science Translational Medicine,2018,10(433):eaap8793.
[11] CASAS-AROZAMENA C,DIAZ E,MOIOLA CP,et al.Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer［J］.Journal of Clinical Medicine,2020,9(2):585.
[12] NAIR N,CAMACHO-VANEGAS O,RYKUNOV D,et al.Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer:a prospective cross-sectional study［J］.PLoS Medicine,2016,13(12):e1002206.
[13] MARTIGNETTI JA,PANDYA D,NAGARSHETH N,et al.Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy［J］.Cold Spring Harbor Molecular Case Studies,2018,4(6):a003269.
[14] ASHWORTH T.A case of cancer in which cells similar to those in the tumours were seen in the blood after death［J］.Australasian Medical Journal,1869,14:146-147.
[15] PANTEL K,BRAKENHOFF RH.Dissecting the metastatic cascade［J］.Nature Reviews Cancer,2004,4(6):448-456.
[16] GHOSSEIN RA,BHATTACHARYA S,ROSAI J.Molecular detection of micrometastases and circulating tumor cells in solid tumors［J］.Clinical Cancer Research,1999,5(8):1950-1960.
[17] MANDEL P,METAIS P.Les acides nucléiques du plasma sanguin chez l’ homme ［Nuclear Acids In Human Blood Plasma］ ［J］.Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales,1948,142(3-4):241-243.
[18] FENG W,JIA N,JIAO H,et al.Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer［J］.Journal of Translational Medicine,2021,19(1):51.
[19] MAIDA Y,TAKAKURA M,NISHIUCHI T,et al.Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium［J］.Cancer Medicine,2016,5(2):304-314.
[20] DE BRUYN C,BAERT T,VAN DEN BOSCH T,et al.Circulating transcripts and biomarkers in uterine tumors:is there a predictive role ［J］.Current Oncology Reports,2020,22(2):12.
[21] TORRES A,TORRES K,PESCI A,et al.Deregulation of miR-100,miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma［J］.BMC Cancer,2012,12:369.
[22] TORRES A,TORRES K,PESCI A,et al.Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients［J］.International Journal of Cancer,2013,132(7):1633-1645.
[23] SRIVASTAVA A,MOXLEY K,RUSKIN R,et al.A Non-invasive liquid biopsy screening of urine-derived exosomes for mirnas as biomarkers in endometrial cancer patients［J］.The AAPS journal,2018,20(5):82.
[24] KOMMOSS S,HARTKOPF AD,KRAMER B,et al.Disseminated tumor cells are not associated with established risk factors,L1CAM immunoreactivity and outcome in endometrial carcinoma［J］.Journal of Cancer Research and Clinical Oncology,2017,143(11):2183-2188.
[25] WALTER CB,TARAN FA,WALLWIENER M,et al.Prevalence and prognostic value of disseminated tumor cells in primary endometrial,cervical and vulvar cancer patients［J］.Future Oncology(London,England),2014,10(1):41-48.
[26] BOGANI G,LIU MC,DOWDY SC,et al.Detection of circulating tumor cells in high-risk endometrial cancer［J］.Anticancer research,2015,35(2):683-687.
[27] NI T,SUN X,SHAN B,et al.Detection of circulating tumour cells may add value in endometrial cancer management［J］.European Journal of Obstetrics Gynecology and Reproductive Biology,2016,207:1-4.
[28] ALONSO-ALCONADA L,MUINELO-ROMAY L,MADISSOO K,et al.Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer［J］.Molecular Cancer,2014,13:223.
[29] LEMECH CR,ENSELL L,PATERSON JC,et al.Enumeration and molecular characterisation of circulating tumour cells in endometrial cancer［J］.Oncology,2016,91(1):48-54.
[30] LIN H,BALIC M,ZHENG S,et al.Disseminated and circulating tumor cells:Role in effective cancer management［J］.Critical Reviews in Oncology/Hematology,2011,77(1):1-11.
[31] CICCHILLITTI L,CORRADO G,DE ANGELI M,et al.Circulating cell-free DNA content as blood based biomarker in endometrial cancer［J］.Oncotarget,2017,8(70):115230-115243.
[32] DOBRZYCKA B,TERLIKOWSKI SJ,MAZUREK A,et al.Circulating free DNA,p53 antibody and mutations of KRAS gene in endometrial cancer［J］.International Journal of Cancer,2010,127(3):612-621.
[33] MALENTACCHI F,TURRINI I,ZEPPONI F,et al.Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer:predictable tool of relapse［J］.Anticancer Drugs,2020,31(10):1091-1095.
[34] BOLIVAR AM,LUTHRA R,MEHROTRA M,et al.Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA:identification of plasma-based,tumor-associated mutations in early stage patients［J］.Modern Pathology,2019,32(3):405-414.
[35] SHINTANI D,HIHARA T,OGASAWARA A,et al.Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer［J］.International Journal of Gynecological Cancer,2020,30(9):1340-1346.
[36] VAN DEN HEERIK ASVM,HOREWEG N,DE BOER SM,et al.Adjuvant therapy for endometrial cancer in the era of molecular classification:radiotherapy,chemoradiation and novel targets for therapy［J］.International Journal of Gynecological Cancer,2021,31(4):594-604.
[37] OTT PA,BANG YJ,BERTON-RIGAUD D,et al.Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer:results from the KEYNOTE-028 study［J］.Journal of Clinical Oncology,2017,35(22):2535-2541.
[38] YU F,MAKRIGIORGOS A,LEONG KW,et al.Sensitive detection of microsatellite instability in tissues and liquid biopsies:Recent developments and updates［J］.Computational and Structural Biotechnology Journal,2021,19:4931-4940.
[39] GILSON P,MERLIN JL,HARLE A.Detection of microsatellite instability:state of the art and future applications in circulating tumour DNA (ctDNA) ［J］.Cancers (Basel),2021,13(7):1491.
[40] MUSACCHIO L,CARUSO G,PISANO C,et al.PARP inhibitors in endometrial cancer:current status and perspectives［J］.Cancer Management and Research,2020,12:6123-6135.
[41] ABBINK K,ZUSTERZEEL PL,GEURTS-MOESPOT AJ,et al.HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients［J］.Tumour Bbiology,2018,40(2):1010428318757103.
[42] DIEHL F,SCHMIDT K,CHOTI MA,et al.Circulating mutant DNA to assess tumor dynamics［J］.Nature Medicine,2008,14:985-990.
[43] MOSS EL,GORSIA DN,COLLINS A,et al.Utility of circulating tumor dna for detection and monitoring of endometrial cancer recurrence and progression［J］.Cancers (Basel),2020,12(8):2231.